Iovance Biotherapeutics (IOVA) Provides Regulatory Update for Lifileucel Potency Assays, BLA Submission Now Expected H1 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Wall St set for flat open as Middle East jitters ease, Netflix slumps
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Stocks off two-month low as fear of Middle East escalation eases
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- Netflix, Tesla, Amex, P&G fall premarket; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Iovanace Biotherapeutics (IOVA) Has Strong Cash Cushion Even as CEO Exit Adds to Uncertainties - Mizuho
May 19, 2021 12:42 PM EDTMizuho Securities analyst Mara Goldstein weighed in on Iovanace Biotherapeutics (NASDAQ: IOVA) after the company announced that Maria Fardis, Ph.D. will resign as President and CEO of the company following today's regulatory setback.
"The commercial potential for lifileucel remains but the question... More
Iovanace Biotherapeutics (IOVA) PT Lowered to $33 at Stifel on BLA Push
May 19, 2021 8:05 AM EDTStifel analyst Benjamin Burnett lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $33.00 (from $49.00) while maintaining a Buy rating.
The analyst commented, "Although yesterday's update has us scratching our heads and leaves us with a number of outstanding questions, we remain... More
Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at Chardan Capital Markets on BLA Delay
May 19, 2021 7:58 AM EDTChardan Capital Markets analyst Geulah Livshits lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $51.00 (from $54.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, after market close, Iovance Biotherapeutics announced revised guidance for BLA filing on tumor infiltrating lymphocyte (TIL)... More
